Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme

AIM: To evaluate the potential for semaglutide to help people with type 2 diabetes (T2D) achieve glycated haemoglobin (HbA1c) targets while avoiding unwanted outcomes, such as weight gain, hypoglycaemia and gastrointestinal (GI) side effects. MATERIALS AND METHODS: Data from the phase IIIa SUSTAIN 1...

Descripción completa

Detalles Bibliográficos
Autores principales: DeVries, J. Hans, Desouza, Cyrus, Bellary, Srikanth, Unger, Jeffrey, Hansen, Oluf K. H., Zacho, Jeppe, Woo, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175309/
https://www.ncbi.nlm.nih.gov/pubmed/29862621
http://dx.doi.org/10.1111/dom.13396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6175309/
https://www.ncbi.nlm.nih.gov/pubmed/29862621
http://dx.doi.org/10.1111/dom.13396

Ejemplares similares